Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Calculi | 6 | 2023 | 47 | 2.270 |
Why?
|
| Hyperoxaluria, Primary | 4 | 2024 | 13 | 2.170 |
Why?
|
| Nutrition Therapy | 3 | 2017 | 23 | 1.690 |
Why?
|
| Hemolytic-Uremic Syndrome | 3 | 2022 | 48 | 1.450 |
Why?
|
| Hematuria | 3 | 2022 | 83 | 1.270 |
Why?
|
| Ascitic Fluid | 2 | 2017 | 84 | 1.130 |
Why?
|
| Flank Pain | 2 | 2016 | 10 | 1.120 |
Why?
|
| Peritoneal Dialysis | 2 | 2017 | 140 | 0.980 |
Why?
|
| Immunosuppressive Agents | 3 | 2018 | 1431 | 0.910 |
Why?
|
| Kidney | 5 | 2018 | 2121 | 0.840 |
Why?
|
| Hyperoxaluria | 1 | 2022 | 5 | 0.840 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2022 | 65 | 0.780 |
Why?
|
| Kidney Failure, Chronic | 3 | 2017 | 955 | 0.730 |
Why?
|
| Kidney Diseases | 2 | 2022 | 694 | 0.690 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2018 | 17 | 0.610 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 761 | 0.610 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2009 | 63 | 0.600 |
Why?
|
| Nephrotic Syndrome | 1 | 2018 | 54 | 0.600 |
Why?
|
| Cystinuria | 1 | 2017 | 4 | 0.590 |
Why?
|
| Kidney Transplantation | 3 | 2024 | 760 | 0.590 |
Why?
|
| Chylous Ascites | 1 | 2017 | 25 | 0.570 |
Why?
|
| Renal Nutcracker Syndrome | 1 | 2016 | 7 | 0.560 |
Why?
|
| Renal Insufficiency | 2 | 2017 | 310 | 0.530 |
Why?
|
| Cat-Scratch Disease | 1 | 2015 | 34 | 0.490 |
Why?
|
| Recommended Dietary Allowances | 3 | 2017 | 24 | 0.430 |
Why?
|
| Rituximab | 1 | 2018 | 1593 | 0.420 |
Why?
|
| Micronutrients | 3 | 2017 | 75 | 0.410 |
Why?
|
| Plant Proteins | 3 | 2017 | 133 | 0.400 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2022 | 751 | 0.390 |
Why?
|
| Dietary Proteins | 3 | 2017 | 255 | 0.370 |
Why?
|
| Adolescent | 19 | 2022 | 32744 | 0.370 |
Why?
|
| Child | 18 | 2023 | 30547 | 0.310 |
Why?
|
| Urinary Tract Infections | 2 | 2003 | 343 | 0.300 |
Why?
|
| Calcium, Dietary | 2 | 2017 | 51 | 0.280 |
Why?
|
| Renal Dialysis | 2 | 2024 | 922 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 2653 | 0.280 |
Why?
|
| Ascorbic Acid | 2 | 2017 | 131 | 0.270 |
Why?
|
| Oxalates | 2 | 2022 | 32 | 0.260 |
Why?
|
| Caregivers | 3 | 2022 | 753 | 0.250 |
Why?
|
| Vitamin D | 2 | 2017 | 261 | 0.240 |
Why?
|
| Computed Tomography Angiography | 2 | 2016 | 247 | 0.240 |
Why?
|
| Humans | 32 | 2024 | 270806 | 0.240 |
Why?
|
| Ultrafiltration | 1 | 2004 | 25 | 0.230 |
Why?
|
| Water Intoxication | 1 | 2003 | 1 | 0.230 |
Why?
|
| Ganciclovir | 1 | 2024 | 194 | 0.220 |
Why?
|
| Blood Volume | 1 | 2004 | 107 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 3 | 2015 | 3181 | 0.220 |
Why?
|
| Nephrolithiasis | 1 | 2023 | 14 | 0.220 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2003 | 12 | 0.220 |
Why?
|
| Nephrocalcinosis | 1 | 2023 | 15 | 0.220 |
Why?
|
| Infant, Newborn | 4 | 2022 | 8699 | 0.210 |
Why?
|
| Early Diagnosis | 1 | 2024 | 314 | 0.210 |
Why?
|
| Algorithms | 2 | 2024 | 3900 | 0.210 |
Why?
|
| Child, Preschool | 9 | 2022 | 17049 | 0.210 |
Why?
|
| Coatomer Protein | 1 | 2022 | 33 | 0.200 |
Why?
|
| Mycophenolic Acid | 2 | 2015 | 153 | 0.200 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 1035 | 0.190 |
Why?
|
| RNAi Therapeutics | 1 | 2021 | 44 | 0.190 |
Why?
|
| Organ Transplantation | 1 | 2024 | 203 | 0.190 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 495 | 0.170 |
Why?
|
| Diagnosis, Differential | 3 | 2022 | 4831 | 0.170 |
Why?
|
| Male | 15 | 2022 | 128400 | 0.170 |
Why?
|
| Body Weight | 1 | 2004 | 1311 | 0.160 |
Why?
|
| Delphi Technique | 1 | 2020 | 275 | 0.160 |
Why?
|
| Patient Outcome Assessment | 1 | 2020 | 245 | 0.160 |
Why?
|
| Infant | 7 | 2022 | 13989 | 0.160 |
Why?
|
| Cost of Illness | 2 | 2019 | 504 | 0.160 |
Why?
|
| Dyspnea | 1 | 2022 | 420 | 0.160 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2018 | 4 | 0.160 |
Why?
|
| Plasma Exchange | 2 | 2009 | 104 | 0.150 |
Why?
|
| Young Adult | 7 | 2023 | 22226 | 0.150 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2017 | 25 | 0.150 |
Why?
|
| Hemodiafiltration | 1 | 2017 | 19 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2024 | 1253 | 0.140 |
Why?
|
| Adenine | 1 | 2020 | 672 | 0.140 |
Why?
|
| Ureteral Obstruction | 1 | 2018 | 146 | 0.140 |
Why?
|
| Methionine | 1 | 2017 | 170 | 0.140 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 1414 | 0.140 |
Why?
|
| Attitude to Health | 1 | 2019 | 434 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2022 | 755 | 0.130 |
Why?
|
| Ureter | 1 | 2018 | 219 | 0.130 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2016 | 88 | 0.130 |
Why?
|
| Catheterization, Peripheral | 1 | 2017 | 153 | 0.130 |
Why?
|
| Consensus | 1 | 2020 | 1105 | 0.130 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2015 | 24 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2024 | 1195 | 0.120 |
Why?
|
| Parents | 2 | 2022 | 1084 | 0.120 |
Why?
|
| Focus Groups | 3 | 2022 | 282 | 0.120 |
Why?
|
| Cyclosporine | 1 | 2015 | 292 | 0.120 |
Why?
|
| Female | 14 | 2022 | 148969 | 0.120 |
Why?
|
| Triglycerides | 1 | 2017 | 612 | 0.120 |
Why?
|
| Urogenital Abnormalities | 1 | 2016 | 174 | 0.120 |
Why?
|
| Outpatients | 1 | 2017 | 463 | 0.110 |
Why?
|
| Tacrolimus | 1 | 2015 | 347 | 0.110 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 380 | 0.110 |
Why?
|
| Prednisone | 1 | 2015 | 1033 | 0.100 |
Why?
|
| Communication | 1 | 2018 | 839 | 0.100 |
Why?
|
| Graft Survival | 1 | 2015 | 1082 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2015 | 1428 | 0.100 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 471 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 1129 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 1 | 2016 | 621 | 0.090 |
Why?
|
| Decision Making | 1 | 2018 | 1251 | 0.090 |
Why?
|
| Adult | 7 | 2023 | 81998 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 2344 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1569 | 0.080 |
Why?
|
| Diet | 1 | 2017 | 1480 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2020 | 33741 | 0.080 |
Why?
|
| Australia | 2 | 2019 | 261 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 4328 | 0.080 |
Why?
|
| Biopsy | 1 | 2015 | 3483 | 0.070 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2009 | 191 | 0.070 |
Why?
|
| Canada | 2 | 2019 | 440 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 5102 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6255 | 0.060 |
Why?
|
| Acyclovir | 1 | 2024 | 79 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 3408 | 0.060 |
Why?
|
| Quality of Life | 1 | 2018 | 4775 | 0.060 |
Why?
|
| Hematocrit | 1 | 2004 | 151 | 0.060 |
Why?
|
| Bias | 1 | 2024 | 216 | 0.050 |
Why?
|
| Bicarbonates | 1 | 2023 | 105 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5778 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2003 | 151 | 0.050 |
Why?
|
| Time Factors | 1 | 2015 | 13021 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2024 | 336 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 3243 | 0.050 |
Why?
|
| Cause of Death | 1 | 2024 | 788 | 0.050 |
Why?
|
| Adenine Phosphoribosyltransferase | 1 | 2020 | 7 | 0.050 |
Why?
|
| Urolithiasis | 1 | 2020 | 6 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 15213 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2020 | 39834 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2020 | 108 | 0.040 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2019 | 30 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 325 | 0.040 |
Why?
|
| Survival | 1 | 2019 | 183 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2003 | 1610 | 0.040 |
Why?
|
| Growth | 1 | 2019 | 125 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1407 | 0.040 |
Why?
|
| Middle Aged | 2 | 2022 | 90348 | 0.040 |
Why?
|
| Family Health | 1 | 2019 | 349 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2004 | 1571 | 0.040 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 93 | 0.040 |
Why?
|
| Transplants | 1 | 2018 | 50 | 0.040 |
Why?
|
| Iohexol | 1 | 2017 | 56 | 0.040 |
Why?
|
| Acute Disease | 1 | 2003 | 2496 | 0.040 |
Why?
|
| RNA Interference | 1 | 2021 | 1387 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 205 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 4375 | 0.040 |
Why?
|
| Triiodobenzoic Acids | 1 | 2017 | 69 | 0.040 |
Why?
|
| PAX2 Transcription Factor | 1 | 2016 | 37 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2018 | 322 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2016 | 41 | 0.030 |
Why?
|
| Patient Preference | 1 | 2019 | 229 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 3532 | 0.030 |
Why?
|
| Parent-Child Relations | 1 | 2018 | 266 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2016 | 190 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 2196 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 417 | 0.030 |
Why?
|
| Anxiety | 1 | 2022 | 1236 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2018 | 636 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 652 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2023 | 1697 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 4498 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 1089 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2003 | 9290 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 2042 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 763 | 0.020 |
Why?
|
| United States | 2 | 2019 | 15856 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 535 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 1281 | 0.020 |
Why?
|
| Contrast Media | 1 | 2017 | 1499 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6193 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2004 | 13417 | 0.020 |
Why?
|
| Pediatrics | 1 | 2018 | 1189 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2024 | 5676 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1717 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 5465 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 6447 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 6768 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 9475 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 3439 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 4645 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 22481 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 17901 | 0.010 |
Why?
|